{
  "abstract": "Without parallel public health action, reclassifying ketamine risks being a symbolic gesture rather than a strategy to reduce harm, write Adam Winstock, David Nutt, and Caroline Copeland",
  "authors": [
    {
      "affiliations": [
        "Institute of Epidemiology and Health Care, University College London, London, UK"
      ],
      "name": "Adam R Winstock"
    },
    {
      "affiliations": [
        "Neuropsychopharmacology Unit, Division of Brain Sciences, Imperial College London, London, UK"
      ],
      "name": "David J Nutt"
    },
    {
      "affiliations": [
        "Centre for Pharmaceutical Medicine, Institute of Pharmaceutical Science, King’s College London, London, UK",
        "National Programme on Substance Use Mortality, London, UK"
      ],
      "name": "Caroline S Copeland"
    }
  ],
  "title": "Ketamine: reclassification alone will not reduce harms",
  "uid": "c8e99285-5657-5ee5-96c1-dcf8adf72817"
}